Albireo Pharma (ALBO) Reports Q3 Loss of $1.17, Revenues Miss

Albireo Pharma (NASDAQ: ALBO) reported Q3 EPS of ($1.17), versus $0.00 reported last year. Revenue for the quarter came in at $237 thousand versus the consensus estimate of $1.27 million.

“With our Phase 3 clinical trial of A4250 for progressive familial intrahepatic cholestasis (PFIC) progressing according to our plan, we focused in Q3 on driving Phase 3 enrollment, deepening our understanding of cholestatic liver diseases and achieving key regulatory milestones on the way to bringing the first approved pharmacological treatment for PFIC and other cholestatic liver diseases to patients,” said Ron Cooper, President and Chief Executive Officer of Albireo.

For earnings history and earnings-related data on Albireo Pharma (ALBO) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year